Non-small Cell Lung Cancer
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
You can participate in this study for as long as your study doctor determines that you are benefiting from the study treatment.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participant must have Stage IV Squamous Non-Small Cell lung cancer confirmed by histology or cytology
Participant must not be enrolled in another clinical trial
Participant must not have undergone systemic radiotherapy, major surgery or received any investigational therapy within 4 weeks prior to study entry
Participant must not have a history of arterial or venous embolism within 6 months prior to study entry
Participant must have discontinued any investigational product or non approved use of a drug or device from a clinical trial more than 30 days prior to the first day of study treatment
Participant must not have received previous chemotherapy for advanced NSCLC, however participants who have received adjuvant or neoadjuvant chemotherapy are eligible if the last administration of the prior regimens occurred at least 1 year prior to study entry
Female participant must not be pregnant or breastfeeding